CytRx to Present at the Biotech Showcase 2013 Conference

  CytRx to Present at the Biotech Showcase 2013 Conference

Biotech Showcase 2013

Business Wire

LOS ANGELES -- January 2, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, announced that President and CEO Steven A.
Kriegsman and Vice President, Business Development David J. Haen will present
at the Biotech Showcase 2013 conference on Tuesday, January 8, 2013, at 2:15
p.m. Pacific time. The conference is being held at the Parc 55 Wyndham hotel
in San Francisco.

A webcast of the presentation will be available on the Company’s website at
http://cytrx.com/investors/presentations.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. The CytRx oncology pipeline includes two programs in
clinical development for cancer indications: aldoxorubicin (formerly known as
INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate
aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as
a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical
trial primarily in the same indication, and has initiated a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors, a
Phase 2 trial for patients with advanced pancreatic ductal adenocarcinomas and
a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients
with advanced solid tumors. The Company has held a positive meeting with the
FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a
therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy, and is planning to submit a special
protocol assessment related to this trial. Tamibarotene is being tested in a
double-blind, placebo-controlled, international Phase 2b clinical trial in
patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial
as a treatment for acute promyelocytic leukemia (APL). The Company completed
its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2
clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and
plans to seek a partner for further development of bafetinib. For more
information about CytRx Corporation, visit www.cytrx.com.

Contact:

Investor Relations
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com
 
Press spacebar to pause and continue. Press esc to stop.